Skip Navigation


Annals of Oncology Advance Access originally published online on February 9, 2006
Annals of Oncology 2006 17(5):773-779; doi:10.1093/annonc/mdl004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/5/773    most recent
mdl004v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Last, K.
Right arrow Articles by Joel, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Last, K.
Right arrow Articles by Joel, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

The activity of methylated and non-methylated selenium species in lymphoma cell lines and primary tumours

K. Last, L. Maharaj, J. Perry, S. Strauss, J. Fitzgibbon, T. A. Lister and S. Joel*

Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital, London, UK

* Correspondence to: Dr S. Joel, Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital, West Smithfield, London EC1A 7BE, UK. Tel: +44-207-601-8924; Fax : +44-207-600-4265; E-mail: s.p.joel{at}qmul.ac.uk

Background: Diffuse large B-cell lymphoma patients with low serum selenium concentration at presentation have a lower response rate and overall survival than patients with higher serum selenium. The co-administration of selenium with conventional chemotherapy may be useful in these patients.

Patients and methods: We investigated the activity of two selenium species, methylseleninic acid (MSA) and selenodiglutathione (SDG) in a panel of human lymphoma cell lines and in a primary lymphoma culture system.

Results: Both compounds demonstrated cytostatic and cytotoxic activity with EC50 values in the range 1.0–10.2 µM. Cell death was associated with an increase in the sub-G1 (apoptotic) fraction by flow cytometry and was not preceded by any obvious cell cycle arrest. SDG, but not MSA, resulted in marked increases in intracellular ROS, particularly in CRL2261 and SUD4 cells in which the cytotoxic activity of SDG was partly, or completely, inhibited by n-acetyl cysteine, suggesting a dependence on ROS for activity in some cells. Both MSA and SDG showed a concentration dependent reduction in percentage viability after a 2-day exposure in primary lymphoma cultures, with EC50 values in the range 39–300 µM and 9–28 µM, respectively.

Conclusion: The selenium compounds MSA and SDG induce cell death in lymphoma cell lines and primary lymphoma cultures, which with SDG may be partly attributable to the generation of ROS.

Key words: lymphoma, methyseleninic acid, primary culture, selenium, selenodiglutathione


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
S. Juliger, H. Goenaga-Infante, T. A. Lister, J. Fitzgibbon, and S. P. Joel
Chemosensitization of B-Cell Lymphomas by Methylseleninic Acid Involves Nuclear Factor-{kappa}B Inhibition and the Rapid Generation of Other Selenium Species
Cancer Res., November 15, 2007; 67(22): 10984 - 10992.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.